Clinical Care

About Clinical Care

Taking care of patients and their communities is at the heart of what hospitals do, and that wouldn’t be possible without the clinical services that hospitals provide. These services touch all aspects of a hospital’s operations, ranging from the emergency department to behavioral health. Through its numerous area-specific groups, CHA provides advocacy and representation on all aspects of operations — guiding hospitals in meeting regulatory, legal, and licensing requirements.

State Issues Public Health Officer Order on Hospital and SNF Visitation

The California Department of Public Health (CDPH) issued a public health officer order on Aug. 5 requiring general acute care hospitals, skilled-nursing facilities, and intermediate care facilities to either: (1) verify that indoor visitors are fully vaccinated, or (2) verify documentation of a negative COVID-19 test. The health order includes the following requirements: 

Medical Certification Needed for Medical Baseline Programs

In 2020, the major power utilities in California waived the requirement for medical practitioners to certify a patient’s request to enroll in their medical baseline programs. However, this temporary waiver allowing customers to self-certify their eligibility to enroll ended on June 30, and a signature from a qualified medical practitioner is now required. 

BRN’s Nurse Practitioner Full Practice Authority Regulations Begin

Assembly Bill (AB) 890 (Wood, D-Santa Rosa), which was signed into law on Sept. 29, will authorize a nurse practitioner who meets certain requirements to practice without physician supervision. The new law will improve access to health care by allowing nurse practitioners greater freedom and flexibility to practice in communities with insufficient primary care services. Details about the changes that will be implemented with AB 890 are available here. 

HHHS Withdraws Guidance Requiring Manufacturers to Provide 340B Discount at Contract Pharmacies

The Department of Health & Human Services (HHS) has withdrawn a December 2020 advisory opinion from the Health Resources and Services Administration requiring pharmaceutical manufacturers to sell covered entities 340B drugs at or below the ceiling price when those drugs are distributed through a contract pharmacy.  Earlier this year, AstraZeneca and other drugmakers sued the agency over the opinion. The withdrawal follows a federal judge denying HHS’ request to dismiss AstraZeneca’s challenge.